We, therefore, set out to improve the methodology for assessing TGF-β expression by using the immunohistochemical assessment of nuclear staining in a similar way to other markers in other pathologies [39,40], since, to our knowledge, it had not yet been applied to evaluate TGF-β prognostic relevance in NSCLC. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.